Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin

Archive of all online content

January 01, 2004 - September 01, 2023
Browse by Volumes
  • 2000s
  • 2010s
  • 2020s
  • 2004
  • 2005
  • 2006
  • 2007
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
  • 2019
  • 2020
  • 2021
  • 2022
  • 2023

2005

November
  • November-December 2005; 19 (6) + Index
    November-December 2005 : Vol. 19, Issue 6: 949-1142
September
  • September-October 2005 : Vol. 19, Issue 5: 815-948
July
  • July-August 2005 : Vol. 19, Issue 4: 653-813
May
  • May-June 2005 : Vol. 19, Issue 3: 487-652
March
  • March-April 2005 : Vol. 19, Issue 2: 323-485
January
  • Special Issue on New Anticancer Agents
    January-February 2005 : Vol. 19, Issue 1: 1-322
20042006
Back to top

Current Issue

September-October 2023 (Vol. 37 Issue 5) Table of Contents
In Vivo: 37 (5)

Issue highlights

  • Therapeutic Efficacy of Temsirolimus in a Patient-derived Model of Metastatic Fibrolamellar Hepatocellular Carcinoma
  • Rapid Reduction of CEA and Stable Metastasis in an NRAS-mutant Rectal-Cancer Patient Treated With FOLFIRI and Bevacizumab Combined With Oral Recombinant Methioninase and a Low-Methionine Diet Upon Metastatic Recurrence After FOLFIRI and Bevacizumab Treatment Alone
  • Renieramycin T Derivative DH_22 Induces p53-dependent Apoptosis in Lung Cancer Cells
  • In Vitro Carbon Ion Beam and Gemcitabine Chemoradiation in a Mucoepidermoid Carcinoma Cell Line
  • Determination of the Possible Target Genes of Hepatoma-derived Growth Factor in Hepatoma Cells
Navigate To
In Vivo

© 2023 In Vivo

Powered by HighWire